NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strong 72% YoY revenue growth for the OneRF brain ablation system, signaling robust product demand. Despite the lack of strategic initiative details and shareholder return plans, the financial performance is a significant positive factor. The absence of clear management responses in the Q&A indicates some uncertainty, but the strong product revenue growth outweighs these concerns, leading to a positive sentiment.
Key Financial Performance
Product revenue for the OneRF brain ablation system $2.4 million in Q2 fiscal 2026, grew 72% year-over-year compared to $1.4 million in Q2 fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product revenue growth: Product revenue for the OneRF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million compared to $1.4 million in the second quarter of fiscal 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Buch Ladenburg
CEO Director
Co Inc
Conference Today
Dave Chief
Destiny Buch
Director Ronald
Division EDT
Division Jeremy
EDT day
Financial Results
Group LLC
Inc Research
Jeremy Pearlman
LLC Research
Ladenburg Thalmann
Maxim Group
Mr Dave
Officer Dave
Officer Destiny
Officer Mr
Officer NeuroOne
Pearlman Maxim
President CEO
Research Division
Ronald McClurg
Technologies Financial
Technologies President
Thalmann Co
gentleman NeuroOne
NMTC Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a strong 72% YoY revenue growth for the OneRF brain ablation system, signaling robust product demand. Despite the lack of strategic initiative details and shareholder return plans, the financial performance is a significant positive factor. The absence of clear management responses in the Q&A indicates some uncertainty, but the strong product revenue growth outweighs these concerns, leading to a positive sentiment.
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
Unknown2-17
The earnings call reveals several concerns: a decrease in product and license revenue, increased net loss, and reduced cash reserves. While there are positive clinical outcomes and ongoing strategic partnerships, the company's avoidance of specific operational details and reliance on Zimmer for sales and marketing raise uncertainties. The Q&A section highlights operational risks, market penetration challenges, and competitive pressures. Despite some positive product developments, the overall sentiment is negative due to financial underperformance and unclear future guidance.
NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript
Positive8-14
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
NMTC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
